Head-To-Head Review: biote (NASDAQ:BTMD) vs. Jinhua Marine Biological (OTCMKTS:JNMB)

biote (NASDAQ:BTMD) and Jinhua Marine Biological (OTCMKTS:JNMB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares biote and Jinhua Marine Biological’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	5.20%	-32.41%	22.26%
Jinhua Marine Biological	N/A	N/A	N/A

Institutional and Insider Ownership

21.7% of biote shares are held by institutional investors. 13.9% of biote shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares biote and Jinhua Marine Biological”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
biote	$185.36 million	1.75	$3.32 million	$0.26	23.00
Jinhua Marine Biological	N/A	N/A	N/A	N/A	N/A

biote has higher revenue and earnings than Jinhua Marine Biological.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for biote and Jinhua Marine Biological, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	0	0	4	0	3.00
Jinhua Marine Biological	0	0	0	0	0.00

biote currently has a consensus price target of $8.39, suggesting a potential upside of 40.26%. Given biote’s stronger consensus rating and higher probable upside, equities research analysts clearly believe biote is more favorable than Jinhua Marine Biological.

Summary

biote beats Jinhua Marine Biological on 8 of the 9 factors compared between the two stocks.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

About Jinhua Marine Biological

Jinhua Marine Biological (USA), Inc. develops allopelagic materials, biological medicines, pesticides, environmental protection products, and products for the home. It offers health products, including Xiduoan, which is used for strengthening and adjusting the immune system. The company also introduces advanced wastewater treatment technology, as well as develops environmental protection projects, including industry/urban wastewater treatment. This business was pursued in three areas: the development, manufacture, distribution and sale of ERGOS Systems directly by the Company; consulting services, and the delivery of marketing and other services to ERGOS network providers.